Loading…
Based on limited metadata, this Warning Letter issued to Strong Fertility Center in October 2019 concerns biologic products, likely related to reproductive medicine and fertility treatments. Without access to the complete letter text or specific subject line, the exact nature of violations cannot be determined from the available information. The warning falls under FDA's biologics regulatory authority, which oversees products derived from biological sources including human tissues and cellular materials commonly used in fertility procedures. Additional documentation would be needed to identify the specific compliance issues cited in this enforcement action.